(Alliance News) - Concerns are increasing over the way Oxford University and AstraZeneca PLC have handled the early readout from trials of their coronavirus vaccine candidate, the Financial Times reported on Wednesday.
https://www.ft.com/content/4583fbf8-b47c-4e78-8253-22efcfa4903a
The results were hailed a success for showing an average efficacy of 70%, a figure reached by pooling the results from cohorts on two different dosing regimens.
AstraZeneca on Monday said one dosing regimen showed vaccine efficacy of 90% when AZD1222 was given as a half dose, followed by a full dose at least one month apart. Another dosing regimen showed 62% efficacy when given as two full doses at least one month apart. The combined analysis from both dosing regimens resulted in an average efficacy of 70%.
But on Tuesday, Moncef Slaoui, the head of Operation Warp Speed, the US government's funding programme for vaccine development, disclosed that the subgroup that scored 90% was limited to people aged 55 or below, a demographic with lower risk of developing severe Covid-19, FT reported.
Oxford and AstraZeneca did not disclose the age breakdown on Monday, when results were released.
AstraZeneca shares closed 2.4% lower on Wednesday in London at 7,810.00 pence each. The stock is down 6.0% so far this week.
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)
